Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Invesco Ltd.

Invesco Ltd. increased its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 1,292.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 312,161 shares of the company's stock after purchasing an additional 289,748 shares during the quarter. Invesco Ltd. owned 0.33% of Scholar Rock worth $13,492,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Barclays PLC raised its holdings in shares of Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after buying an additional 84,118 shares during the period. Geode Capital Management LLC boosted its position in Scholar Rock by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after acquiring an additional 120,489 shares in the last quarter. Vanguard Group Inc. boosted its position in Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Scholar Rock in the 4th quarter worth approximately $274,000. Finally, Rhumbline Advisers grew its holdings in Scholar Rock by 13.2% in the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after purchasing an additional 13,247 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush restated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Stock Performance

NASDAQ SRRK traded down $1.57 during trading hours on Friday, reaching $32.81. The stock had a trading volume of 694,304 shares, compared to its average volume of 1,240,686. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a market cap of $3.11 billion, a P/E ratio of -13.96 and a beta of 0.56. The stock has a fifty day moving average of $32.77 and a 200 day moving average of $35.60.

Insider Activity

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the transaction, the insider now owns 111,084 shares in the company, valued at approximately $4,154,541.60. This represents a 38.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. The trade was a 56.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 250,231 shares of company stock valued at $9,056,086 in the last ninety days. Insiders own 13.30% of the company's stock.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.